Literature DB >> 1713175

Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1.

D Chain1, T Kreizman, H Shapira, S Shaltiel.   

Abstract

Plasmin is shown to specifically cleave vitronectin at the Arg361-Ser362 bond, 18 amino acid residues upstream from the site of the endogenous cleavage which gives rise to the two-chain form of vitronectin in plasma. The cleavage site is established using the exclusive phosphorylation of Ser378 with protein kinase A. As a result of the plasmin cleavage, the affinity between vitronectin and the type-1 inhibitor of plasminogen activator (PAI-1) is significantly reduced. This cleavage is stimulated by glycosaminoglycans, which are known to anchor vitronectin to the extracellular matrix. A mechanism is proposed through which plasmin can arrest its own production by feedback signalling, unleashing PAI-1 from the immobilized vitronectin found in the vascular subendothelium, which becomes exposed at the locus of a hemostatic event.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713175     DOI: 10.1016/0014-5793(91)80810-p

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Plasminogen activators in ischemic stroke: introduction.

Authors:  Gregory J del Zoppo
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 3.  Evidence for an extra-cellular function for protein kinase A.

Authors:  S Shaltiel; I Schvartz; B Korc-Grodzicki; T Kreizman
Journal:  Mol Cell Biochem       Date:  1993-11       Impact factor: 3.396

4.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

5.  Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.

Authors:  Maureen A Shaw; Zhen Gao; Kathryn E McElhinney; Sherry Thornton; Matthew J Flick; Adam Lane; Jay L Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S Mullins
Journal:  J Neurosci       Date:  2017-03-08       Impact factor: 6.167

6.  The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.

Authors:  Z Gechtman; A Belleli; S Lechpammer; S Shaltiel
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

7.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

Authors:  J L Harris; B J Backes; F Leonetti; S Mahrus; J A Ellman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

8.  Tailor made plasmin substrates as potential diagnostic tool to test for mastitis.

Authors:  Floris J Bikker; Gerrit Koop; Naomi B Leusink; Kamran Nazmi; Wendy E Kaman; Henk S Brand; Enno C I Veerman
Journal:  Vet Res Commun       Date:  2014-07-06       Impact factor: 2.459

9.  A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.

Authors:  Christine R Schar; Grant E Blouse; Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

10.  The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors.

Authors:  Hongjie Yuan; Katie M Vance; Candice E Junge; Matthew T Geballe; James P Snyder; John R Hepler; Manuel Yepes; Chian-Ming Low; Stephen F Traynelis
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.